GlassScriptPhysician profile
Nathan P Denell
NPI 1124119482
$3,145.82
in general payments reported to CMS, 2019-2025
23 companies · $35.00 in 2025
The $35.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $1,015 · 2021: $70.91 · 2022: $401 · 2023: $26.89 · 2024: $32.27 · 2025: $35.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $51.12 · Food and Beverage: $43.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $51.12 |
| Food and Beverage | $43.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $604.09 | 2019-2025 | Ozempic |
| Amgen INC. | $414.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $364.77 | 2019-2020 | |
| Allergan, INC. | $310.26 | 2019-2020 | |
| Abbvie INC. | $259.75 | 2020-2023 | Qulipta |
| Comsort, INC | $250.00 | 2019 | |
| Lilly USA, LLC | $163.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $139.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.99 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $94.85 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $93.02 | 2019-2020 | |
| Pfizer INC. | $66.52 | 2019 | |
| Genentech USA, INC. | $64.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.92 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $37.60 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.40 | 2020 | |
| Amarin Pharma, INC. | $22.17 | 2019-2020 | |
| Sanofi Pasteur INC. | $18.52 | 2020 | |
| Dermira, INC. | $16.28 | 2020 | |
| Boston Scientific Corporation | $14.89 | 2020 | |
| Astellas Pharma US INC | $12.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.62 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Denell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.